PV Bulletin

New Drug Product Licensing and Review Work Procedures (Civil Servant Guidelines)

The updated guidelines from MFDS clarify safety monitoring strategies and risk management expectations for drug licensing.

Primary source: Ministry of Food and Drug Safety (MFDS)

PV Impact Brief

Urgency: HighConfidence: high

What changed

MFDS has issued revised guidelines and checklists for new drug applications, specifically addressing the review of safety data and RMPs as part of the marketing authorization process.

Why it matters

These changes aim to streamline the drug licensing process, reducing potential regulatory delays by clarifying expectations around safety monitoring and risk mitigation for marketing authorization holders (MAHs).

Action needed

Marketing authorization holders (MAHs) must align their RMP submissions with the updated MFDS checklists to comply with the new review procedures.

Relevant for
Regulatory Intelligence LeadQPPV
Processes impacted
Country Compliance
Owner

Regulatory Intelligence Lead

Review cadence

Review in the next regulatory intelligence cycle.

Policy change details

Document type
Guideline / SOP
Policy status
revised
Publication date
2026-07-31
Policy change
The MFDS has released the 6th revision of its work procedures for preliminary reviews of drug development. This update streamlines the pre-submission review of clinical trial authorizations (CTA) and preliminary safety assessments to ensure consistency in regulatory oversight.

Key changes

Revised steps for preliminary review of drug development stages. Enhanced focus on consistent application of safety standards during the pre-IND and pre-CTA phases to expedite clinical trial approvals.

Affected workflows

Country Compliance

Responsible groups

Clinical SafetyRegulatory AffairsClinical Operations

PV impact

Clinical trial sponsors must review the revised procedures to ensure their preliminary safety assessments and monitoring plans meet the updated MFDS standards. The 6th revision affects the submission timing and format for safety reviews in the early stages of development, impacting clinical trial safety reporting (GCP) strategies.

View regulator source

Source document details

Extracted documents

Evidence and confidence

Confidence: highSource updated: Jul 31, 2026

Full briefing

Practical implication

Marketing authorization holders (MAHs) must align their RMP submissions with the updated MFDS checklists to comply with the new review procedures.

The Ministry of Food and Drug Safety (MFDS) of South Korea has revised its work procedures for the licensing and review of new drug applications. The guidelines include updated checklists that focus on safety data and Risk Management Plans (RMPs), clarifying the review process and expectations to ensure compliance with current South Korean safety standards.

What changed: MFDS has issued revised guidelines and checklists for new drug applications, specifically addressing the review of safety data and RMPs as part of the marketing authorization process.

Why it matters: These changes aim to streamline the drug licensing process, reducing potential regulatory delays by clarifying expectations around safety monitoring and risk mitigation for marketing authorization holders (MAHs).

Practical implication: Marketing authorization holders (MAHs) must align their RMP submissions with the updated MFDS checklists to comply with the new review procedures.

View original source

Published from the Firecrawl policy change extraction pipeline.

#Safety Signals#final#Reporting Requirement#policy-change#firecrawl-policy-agent#Guideline / SOP#Ministry of Food and Drug Safety (MFDS)

Related updates for your role

publicFDA · USA · Updated Sep 4, 2026

FDA Grants Accelerated Approval to Etcamah for Advanced Breast Cancer

Urgency: High

Regulatory teams must prepare for updating labeling to include details on the new indication and required diagnostic methods, along with planning for the confirmatory studies mandated by the FDA.

Signal ManagementLabelingRegulatory Intelligence Lead
SOP Impact2 SOPs
ConfidenceHigh
Relevant for: Regulatory Intelligence Lead
verifiedRegulatory action: Regulators
Read impact briefarrow_forward
publicMHRA · UK · Updated Sep 4, 2026

Change to the definition of regulated activity with children from 1 September 2026

Urgency: High

Organizations must re-evaluate roles related to children's activities and prepare to request Enhanced DBS checks including access to the Children’s Barred List check starting from 1 September 2026.

Country ComplianceRegulatory Intelligence Lead
SOP Impact1 SOPs
ConfidenceHigh
Relevant for: Regulatory Intelligence Lead
verifiedRegulatory action: Regulators
Read impact briefarrow_forward
publicANSM (France) · France · Updated Sep 7, 2026Translated From French

Recall of Gore Viabahn Endoprosthesis with Bioactive Heparin Coating

Urgency: High

Health establishments receiving affected devices must be notified, and protocols established to ensure compliance with the recall.

Signal ManagementQPPV
SOP Impact1 SOPs
ConfidenceHigh
Relevant for: QPPV, Medical Safety Lead
verifiedRegulatory action: Regulators
Read impact briefarrow_forward
publicANSM (France) · France · Updated Sep 7, 2026Translated From French

Atellica CH Revised C-Reactive Protein (RCRP) Safety Information - Siemens Healthcare Diagnostics

Urgency: High

Laboratories must implement the safety measures as indicated by the action registration number R2625739, effective from the notice date of September 7, 2026.

Signal ManagementQPPV
SOP Impact1 SOPs
ConfidenceHigh
Relevant for: QPPV, Medical Safety Lead
verifiedRegulatory action: Regulators
Read impact briefarrow_forward